Uploaded bySociedad Española de Cardiología
FIDELIO-DKD Trial
The document discusses a secondary analysis of the FIDELIO-DKD trial presented by Gerasimos Filippatos at the Heart Failure 2021 conference. The analysis looked at the effects of finerenone in patients with chronic kidney disease and type 2 diabetes, who either did or did not have a history of heart failure. Of the over 5,700 patients in the main FIDELIO-DKD trial, 436 (7.7%) had a history of heart failure at baseline. The secondary analysis examined cardiovascular outcomes including cardiovascular death, non-fatal heart attack or stroke, and hospitalization for heart failure.
More Related Content
Similar to FIDELIO-DKD Trial
More from Sociedad Española de Cardiología
FIDELIO-DKD Trial
- 1. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Dr. Alejandro Recio Mayoral Unidad Insuficiencia Cardiaca Especializada Unidad Multidisciplinar Hipertensión Pulmonar Hospital Virgen Macarena Sevilla Late-Breaking Trials 1 FIDELIO-DKD trial
- 2. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 Finerenone in patients with chronic kidney disease and type 2 diabetes, with and without a history of heart failure: a secondary analysis of the FIDELIO-DKD trial
- 3. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial 436 (7.7%) had a history of HF at baseline
- 4. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 5. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial CV outcome: CV death, Non fatal MI/stroke, HHF
- 6. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 7. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 8. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 9. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 10. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial
- 11. Alejandro Recio Mayoral FIDELIO-DKDtrial. Heart Failure 2021 Gerasimos Filippatos´s presentation. HF 2021 A secondary analysis of the FIDELIO-DKD trial